Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study

Abstract

To explore the risk factors for in-stent restenosis (ISR) after stent implantation in patients with coronary heart disease (CHD) using logistic regression analysis. From February 2020 to February 2022, 350 patients with CHD after percutaneous coronary intervention (PCI) were divided into a stent stenosis group and a stent nonstenosis group based on coronary angiography results performed 2 years after PCI. Univariate and multivariate logistic regressions were used to analyze the factors related to ISR after coronary stent implantation in patients with CHD. This study was approved by the Ethics Committee of Shandong University of Traditional Chinese Medicine. Patient signed informed consent. Of the 350 patients with CHD, 138 (39.43%) had stent restenosis while 212 did not. Univariate analysis showed that a family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stent increased the risk of restenosis. The incidence of restenosis was higher in the stent group than that in the nonstent group (P < .05). There were no significant differences in the blood lipid level, left ventricular ejection fraction, clopidogrel/ticagrelor or beta-blocker withdrawal, location of culprit vessels, and thrombotic lesions between the 2 groups (P > .05). Multivariate logistic regression analysis showed that family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, aspirin withdrawal, use of conventional doses of statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stenting were risk factors for ISR within 2 years after PCI. A family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 stent implantations, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stenting are risk factors for ISR within 2 years after PCI in patients with CHD.

Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study

“…This study explores for the first time the relationship between SII and DES-ISR in ACS patients and reveals a nearly linear dose-response relationship. Although the findings showed a relatively high rate of ISR (11.28%) at 1 year follow-up, this may be related to the higher proportion of acute ST-segment elevation myocardial infarction (47.3%, data not shown) and current smoking (45.9%) [ 46 , 47 ]. Moreover, we adjusted for many potential confounders to produce more reliable findings.…”

Relationship between serum endothelin-1 and in-stent restenosis following vertebral artery stenting

“…Vascular endothelial injury may occur in patients with peripheral arterial occlusive disease after interventional treatment, reducing secretion of factors that inhibit the proliferation and migration of smooth muscle cells, which may lead to ISR [15]. Damaged vascular endothelial cells may further promote thrombosis and vascular constriction, leading to ISR [16]. Therefore, our goal was to evaluate the damage to vascular endothelial cells following endovascular treatment, which may have important clinical value for predicting ISR occurrence.…”

Atlas of Cell Repertoire Within Neointimal Lesions Is Metabolically Altered in Hypertensive Rats

“…Hypertension has been established as a significant risk factor for neointimal formation following vascular angioplasty. [6][7][8] However, the precise mechanistic pathways through which high blood pressure influences injuryinduced neointimal formation remain largely unexplored. Resistant and conductive arteries undergo distinct vascular remodeling in response to hypertension, with vascular SMCs playing a crucial role in this process.…”